Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology -

CRANBURY, N.J., June 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S. Food and Drug Administration (FDA) on the key protocol design elements of the pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. The Company has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of this year.

John F. Crowley, President and CEO of Amicus stated, "The start of our Phase 3 trial with Amigal is a major milestone for Amicus and highlights our transition into a late-stage development company." Crowley continued, "We are very pleased with the outcome of our interactions with FDA around the design of this pivotal study and are confident we have set the stage for a successful Phase 3 study. We continue to believe that Amigal may be an important treatment option for patients who suffer with Fabry disease and a significant step forward for them and their families."

Raphael Schiffmann, MD, Director of the Institute of Metabolic Disease, Baylor Health Care System Foundation, commented, "Having been involved in Fabry research for more than 15 years and considering the Phase 2 data with migalastat, I am pleased that the Phase 3 trial is st
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... ( www.fuisz.com ) today announced the issuance of U.S. ... Access to On-Line Vendor Information"). Joseph Matus ... a system that allows a customer or potential customer ... database through the on-line vendor,s system to provide the ...
... The American Academy of Family Physicians Foundation is ... Immunization Award winners. These awards recognize family medicine ... in their communities through creative solutions. Monetary grants ... were presented to 16 residents from the following ...
Cached Medicine Technology:Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 2Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 3
(Date:8/31/2014)... (PRWEB) August 31, 2014 MedixSafe has ... ambulance safes and narcotics lockers . ... the MedixSafe brand for distribution worldwide. “We have now ... Emirates.” Lindsay McCollum, MedixSafe Sales Manager , MedixSafe is ... electronic security and network cabling company with over 30 ...
(Date:8/31/2014)... Just in time for Washington’s Indian Summer, Dukes ... Salmon, award winning chowder and legendary sourdough bread ... location , Sunday, September 28, 2014 from 1 pm to ... BBQ culinary delights. Live music will add to the festive ... and Mexico will be featured. “There is no salmon ...
(Date:8/31/2014)... 2014 Recently, BambooIndustry.com, one of the most ... a new selection of bamboo veneers . Additionally, it ... off) for these high quality products. The promotion will last ... spokesman says that its top quality veneers are hot in ... new designs of bamboo veneers. All these items are made ...
(Date:8/31/2014)... August 31, 2014 Stuart Agren, M.D., ... prescribes sublingual immunotherapy to help his patients struggling ... allergies. Dr. Agren said that it has helped many ... in many cases, restored peace of mind. , Nut ... a host of symptoms, including rashes, digestive distress, hay ...
(Date:8/31/2014)... With years of hard work, Delta has ... construction machines. Recently, the company has updated its wheel ... 966 loaders. All these items are guaranteed to be great. ... , It is true that all items in Delta’s ... by machine specialists. The firm is making full efforts to ...
Breaking Medicine News(10 mins):Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2Health News:High Quality Bamboo Veneers from Bambooindustry.com Receive International Attention 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 3Health News:Delta Updates Its Wheel Loader Assortment With A Lot Of Cheap Used Cat 966 Loaders 2
... Desperate Housewives, Star Joins The Wellness Community as ... , , PHILADELPHIA, Sept. 14 /PRNewswire-USNewswire/ ... Desperate Housewives , found himself in a role he hoped never ... his two sisters in late 2008 left Chavira shocked and overwhelmed ...
... , , NCCN is holding ... to discuss the regulatory and operational aspects of research and ... can be made. Scheduled for October 26 - 27 in ... panel discussions on topics that challenge the conduct of oncology ...
... , , WEST PALM BEACH, Fla., ... Cosmetic Bootcamp University program in New York (Oct 10th) ... director for the New York program, this is a ... Bootcamp fills. Designed for residents and fellows in core ...
... , , BURLINGTON, ... major expansion to its product offering with the delivery ... and the integration of the ClearPoint Security Performance Manager ... - The ClearPoint Unified Security Performance and Compliance Manager. ...
... , , ... YORK, Sept. 14 "The Dr. Oz Show," a high octane, ... world-renowned cardiac surgeon Dr. Mehmet Oz, premieres in syndication today (check ... two of the recently announced "Core Team Oz" guest contributors, fashion ...
... , MealsMatter.org Offers Delicious Ways to Keep the ... Sept. 14 As flu season grips the nation with heightened awareness ... method getting left out in the cold. , , ... groups throughout the year, but it,s particularly significant during flu season," said ...
Cached Medicine News:Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 2Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 3Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 4Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 2Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 3Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 2Health News:'The Dr. Oz Show' Premieres Today Nationwide 3Health News:'The Dr. Oz Show' Premieres Today Nationwide 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 5Health News:Protect Your Family With Flu-Fighting Foods 2
Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
... Olympuss extensive line of affordable, high-quality ... our high-performance light sources to provide optimal ... light weight and durable design give you ... effectively and efficiently. And each is fully-autoclavable ...
Medicine Products: